ABCC6 Transporter Contributed to Cisplatin Resistance on Bladder Cancer

Area of Science:

• Urology
• Oncology
• Molecular Biology

Background:

• Bladder cancer (BLCA) is a prevalent malignancy with increasing incidence globally, particularly in Taiwan.
• Cisplatin chemotherapy resistance is a significant obstacle in treating metastatic BLCA, limiting patient response rates.
• Understanding the mechanisms of drug resistance is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To investigate the role of ATP-binding cassette (ABC) transporters in cisplatin resistance in BLCA.
• To identify specific transporters involved in chemoresistance and their underlying mechanisms.
• To explore potential therapeutic targets for overcoming cisplatin resistance in BLCA.

Main Methods:

• Establishment of cisplatin-resistant BLCA cell models (T24 and UMUC3).
• Analysis of ABC transporter expression in resistant cells.
• Investigation of the role of ABCC6 in cisplatin resistance and autophagy.
• Pharmacological inhibition of autophagy using bafilomycin A1 (BafA1) and chloroquine (CQ).

Main Results:

• ABCC6 was identified as a significantly upregulated transporter in cisplatin-resistant BLCA cells.
• ABCC6 knockdown altered autophagy-related markers, suggesting a link between ABCC6 and autophagy.
• Inhibition of autophagy reversed cisplatin resistance in the established BLCA models.
• ABCC6 appears to contribute to cisplatin resistance through the regulation of autophagy.

Conclusions:

• ABCC6 plays a critical role in mediating cisplatin resistance in bladder cancer.
• Autophagy is a key mechanism through which ABCC6 confers chemoresistance.
• Targeting ABCC6 or modulating autophagy presents a promising strategy to overcome cisplatin resistance in BLCA.